David Kirske is CFO & VP at CTI BIOPHARMA CORP (CTIC). They have made 7 open-market trades across 2 companies since 2021, most recently 2026-06-30.
CIK 0001276750
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| XFOR | 167,750 | $434K |
| CTIC | 17,127 | $156K |
| Total | $590K |
Shares reported on the most recent Form 4, priced at the 2026-07-01 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| XFOR | SELL | 2026-06-30 | 2026-07-01 | $4.26 | $36K | -2.9% | -4.3% | -29.9% |
| XFOR | SELL | 2026-05-12 | 2026-05-13 | $4.29 | $73K | -1.5% | -1.2% | +5.5% |
| CTIC | SELL | 2022-12-29 | 2023-01-03 | $6.01 | $487K | -0.9% | -1.9% | -26.6% |
| CTIC | SELL · 10b5-1 | 2022-10-04 | 2022-10-06 | $6.26 | $13K | -10.6% | -12.0% | -5.1% |
| CTIC | SELL | 2022-09-29 | 2022-10-03 | $6.05 | $1.7M | -22.6% | -19.4% | -6.1% |
| CTIC | SELL | 2022-09-16 | 2022-09-20 | $6.02 | $272K | +3.7% | -17.1% | -3.6% |
| CTIC | SELL | 2022-06-17 | 2022-06-17 | $6.21 | $373K | -6.7% | -2.3% | -3.3% |
| CTIC | SELL | 2022-06-14 | 2022-06-16 | $5.50 | $55K | -5.0% | +8.5% | +15.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.